keyword
https://read.qxmd.com/read/38760926/leukemia-cutis-in-relapsed-acute-myeloid-leukemia-a-call-for-distinct-classification
#1
JOURNAL ARTICLE
William J Nahm, Michelle Juarez, Maher Abdul-Hay, Ahan Bhatt, Shane A Meehan, Marianna Shvartsbeyn
BACKGROUND Acute myeloid leukemia is characterized by dysregulated proliferation and maturation arrest of myeloid precursors, precipitating a spectrum of complications. Among these, leukemia cutis refers specifically to ectopic deposition and proliferation of malignant myeloid cells within the skin. This infiltration pathogenesis remains unclear. Although there are numerous reports of leukemia cutis in the setting of acute myeloid leukemia or primary acute myeloid leukemia, there are no specific reports of leukemia cutis in the setting of relapsed acute myeloid leukemia...
May 18, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38758360/impact-of-cladribine-cytarabine-and-g-csf-clag-as-a-bridging-therapy-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-in-relapsed-or-refractory-acute-myeloid-leukemia
#2
JOURNAL ARTICLE
Tong Cui, Huiyu Li, Shiyuan Zhou, Jing Li, Qian Zhu, Wenjuan Zhu, Zaixiang Tang, Xiao Ma, Huiying Qiu, Depei Wu, Xiaojin Wu
The combination of cladribine, cytarabine, and G-CSF (CLAG) has exhibited robust synergistic anti-leukemia activity as an induction therapy (IT) in acute myeloid leukemia (AML). However, the impact of CLAG as a bridging therapy (BT) administered between IT and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with relapsed or refractory (R/R) AML remains uncertain. In this retrospective study, we examined the efficacy of CLAG as a transitional strategy prior to allo-HSCT in R/R AML...
May 17, 2024: Annals of Hematology
https://read.qxmd.com/read/38757924/impact-of-prior-covid-19-infection-on-allogeneic-hematopoietic-stem-cell-transplantation-outcomes
#3
JOURNAL ARTICLE
Aleksandr Siniaev, Marina Popova, Yulia Rogacheva, Valeria Ianbukhtina, Egor Kulagin, Maria Vladovskaya, Sergey Bondarenko, Ivan Moiseev, Alexander D Kulagin
There are limited data on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recipients with prior COVID-19 infection. This single-center retrospective study included 54 adult patients who received allo-HSCT from July 2020 to September 2021 after previous COVID-19 infection and 122 control group patients without a history of COVID-19 who underwent HSCT during the same period, with a median follow-up of 17 months. Median time from COVID-19 to allo-HSCT was 211 days. The incidence of main complications in the post-transplant period was not significantly different between the two groups: deep vein thrombosis (p = ...
May 2024: Clinical Transplantation
https://read.qxmd.com/read/38757047/normothermic-machine-perfusion-reduces-transfusion-requirements-even-after-static-cold-storage-a-1-y-retrospective-single-center-analysis
#4
JOURNAL ARTICLE
Simon Mathis, Gabriel Putzer, Lukas Gasteiger, Stephan Eschertzhuber, Stefan Schneeberger, Benno Cardini, Tobias Hell, Judith Martini
BACKGROUND: Normothermic machine perfusion (NMP) of liver grafts has been shown to reduce intraoperative catecholamine consumption and the need for allogenic blood products after reperfusion compared with organs undergoing classical static cold storage (SCS). This study aimed to investigate the effects of an NMP phase after SCS (NMP after SCS) of liver grafts in terms of postreperfusion hemodynamics and transfusion requirements. METHODS: Eighteen recipients of NMP after SCS grafts were matched according to recipient age, donor age, and model for end-stage liver disease score in a 1:2 ratio with recipients of an SCS graft...
June 2024: Transplantation Direct
https://read.qxmd.com/read/38756760/antifungal-treatment-duration-in-hematology-patients-with-invasive-mold-infections-a-real-life-update
#5
JOURNAL ARTICLE
Vera Portillo, Silvio Ragozzino, Elisavet Stavropoulou, Celine El-Khoury, Pierre-Yves Bochud, Frederic Lamoth, Nina Khanna, Dionysios Neofytos
BACKGROUND: Limited data exist on when and how to stop antifungal treatment (AFT) in patients with invasive mold infections (IMIs) who are immunocompromised. METHODS: This retrospective multicenter study included adult patients with acute myelogenous leukemia and proven/probable IMI (1 January 2010-31 December 2022) in 3 university hospitals. The primary objective was to describe AFT duration and adaptation. Secondary objectives were to investigate the reasons for AFT adjustments and prolongation...
May 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38756667/survival-after-allogeneic-transplantation-according-to-pretransplant-minimal-residual-disease-and-conditioning-intensity-in-patients-with-acute-myeloid-leukemia
#6
JOURNAL ARTICLE
Claudia Núñez-Torrón Stock, Carlos Jiménez Chillón, Fernando Martín Moro, Juan Marquet Palomanes, Miguel Piris Villaespesa, Ernesto Roldán Santiago, Eulalia Rodríguez Martín, Anabelle Chinea Rodríguez, Valentín García Gutiérrez, Gemma Moreno Jiménez, Javier López Jiménez, Pilar Herrera Puente
BACKGROUND: The measurement of minimal residual disease (MRD) by multiparametric flow cytometry (MFC) before hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) is a powerful prognostic factor. The interaction of pretransplant MRD and the conditioning intensity has not yet been clarified. OBJECTIVE: The aim of this study is to analyze the transplant outcomes of patients with AML who underwent HSCT in complete remission (CR), comparing patients with positive MRD (MRD+) and negative MRD (MRD-) before HSCT, and the interaction between conditioning intensity and pre-HSCT MRD...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38756666/spontaneous-remission-of-choroidal-involvement-by-chronic-myelomonocytic-leukemia-a-case-report
#7
Elisa Diral, Gloria Catalano, Maria Vittoria Cicinelli, Andrea Distefano, Sara Mastaglio, Luca Vago, Maria Teresa Lupo Stanghellini, Massimo Bernardi, Maurilio Ponzoni, Fabio Ciceri, Matteo G Carrabba
Chronic myelomonocytic leukemia (CMML) is a rare hematological disorder characterized by variable risk of evolution to acute myeloid leukemia; to date, allogeneic stem cell transplantation is the only curative treatment. We report a case of choroidal involvement in a woman affected by CMML and presenting only with visual impairment. The patient was initially evaluated for an intensive therapeutic approach, but after biopsy the ocular lesion spontaneously regressed. Thus a "watch and wait" strategy was preferred...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38755522/is-intensive-chemotherapy-and-allogeneic-stem-cell-transplantation-mandatory-for-curing-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-in-young-patients-in-the-era-of-multitarget-agents
#8
REVIEW
Sang Kyun Sohn, Jung Min Lee, Youngeun Jang, Yunji Lee, Jihyun Na, Hee Jeong Cho, Joon Ho Moon, Dong Won Baek
INTRODUCTION: The treatment outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) have improved with various tyrosine kinase inhibitors (TKIs) and bispecific T-cell engagers. Although allogeneic stem cell transplantation (allo-SCT) is the standard treatment for young patients with Ph+ALL, its role remains debatable in the era of TKIs and blinatumomab. AREAS COVERED: There are some issues regarding Ph+ALL. First, do young patients require intensive chemotherapy (IC) in the era of multitarget agents? Second, which TKI is preferred for frontline therapy? Third, should allo-SCT be performed in patients achieving complete remission with ponatinib and IC? Fourth, can chemo-free treatment lead to a cure without allo-SCT? We searched relevant literature from the last 30 years on PubMed; reviewed the role of chemo-free therapies and combinations of ponatinib and IC; and assessed the necessity of allo-SCT in young patients with Ph+ALL...
May 16, 2024: Expert Review of Hematology
https://read.qxmd.com/read/38755458/total-body-irradiation-versus-thiotepa-busulfan-based-conditioning-regimens-for-myeloablative-allogeneic-stem-cell-transplantation-in-adults-with-acute-lymphoblastic-leukemia
#9
JOURNAL ARTICLE
Elvira Mora, Juan Montoro, Aitana Balaguer, Montserrat Rovira, Monica Cabrero, Inmaculada Heras, Josep-Maria Ribera, Gabriela Antelo, Ana Africa Martin, Oriana Lopez Godino, Anna Torrent, Marta Villalba, Pedro Chorao, Miguel A Sanz, Jaime Sanz
Total body irradiation (TBI)-based conditioning regimens are generally recommended for allogeneic HSCT (allo-HSCT) in patients with acute lymphoblastic leukemia (ALL). Recent evidence suggests that modern chemotherapy-based regimens may be as effective. This multicenter retrospective study compared the clinical outcomes of myeloablative allo-HSCT with thiotepa, busulfan, and cyclophosphamide/fludarabine (TTB) to TBI-based conditioning. Between 2002 to 2018, 63 and 114 patients received TTB- and TBI-based conditioning regimens, respectively...
May 16, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38754915/therapeutic-inducers-of-natural-killer-cell-killing-thinkk-preclinical-assessment-of-safety-and-efficacy-in-allogeneic-hematopoietic-stem-cell-transplant-settings
#10
JOURNAL ARTICLE
Nicolas Poirier, Valérie Paquin, Séverine Leclerc, Véronique Lisi, Carolina Marmolejo, Hicham Affia, Paulo Cordeiro, Yves Théorêt, Elie Haddad, Gregor Andelfinger, Vincent Philippe Lavallée, Michel Duval, Sabine Herblot
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the standard of care for chemotherapy-refractory leukemia patients, but cure rates are still dismal. To prevent leukemia relapse following HSCT, we aim to improve the early graft-versus-leukemia effect mediated by natural killer (NK) cells. Our approach is based on the adoptive transfer of Therapeutic Inducers of Natural Killer cell Killing (ThINKK). ThINKK are expanded and differentiated from HSC, and exhibit blood plasmacytoid dendritic cell (pDC) features...
May 15, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38754400/a-multicentre-randomized-trial-in-adults-with-de-novo-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-to-assess-the-efficacy-of-ponatinib-versus-imatinib-in-combination-with-low-intensity-chemotherapy-to-compare-end-of-therapy-with-indication
#11
JOURNAL ARTICLE
Fabian Lang, Heike Pfeifer, Monika Brüggemann, Eva Hermann, Hubert Serve, Nicola Goekbuget
Introduction Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) is treated as standard of care (SoC) by imatinib based treatment combined with induction and consolidation chemotherapy followed by allogeneic stem cell transplantation (SCT) in first remission. The German Multicenter ALL Study Group for Adult ALL (GMALL) reports about a trial to evaluate the impact of ponatinib based therapy, blinatumomab (blina) treatment for suboptimal responders and the possibility of omission of SoC Allo SCT in optimal responders entitled GMALL-EVOLVE...
May 16, 2024: Oncology Research and Treatment
https://read.qxmd.com/read/38754066/hematopoietic-stem-cell-transplantation-exploring-the-latest-advances-and-gaps-in-disparities-psychosocial-and-symptom-management-interventions-and-chronic-graft-versus-host-disease-care
#12
REVIEW
Andrew D Trunk, Michelle Guo, Laura Budvytyte, Nadia S Islam, Nandita Khera, Betty K Hamilton, Hermioni L Amonoo
Although allogeneic hematopoietic cell transplantation (HCT) offers a potential for cure for many patients with advanced hematologic malignancies and bone marrow failure or immunodeficiency syndromes, it is an intensive treatment and accompanied by short- and long-term physical and psychological symptoms requiring specialized care. With substantial advances in therapeutic approaches for HCT and supportive care, HCT survivors experience less morbidity and mortality. However, disparities in both HCT access and outcomes persist, and HCT survivors and their caregivers often lack access to much-needed psychosocial care...
June 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38753703/donor-recipient-chimeric-cells-drcc-transplantation-as-the-bridging-therapy-for-mitigating-total-body-irradiation-induced-injury
#13
JOURNAL ARTICLE
Maria Siemionow, Krzysztof Bieda, Katarzyna Stawarz, Malgorzata Cyran, Lucile Chambily, Krzysztof Kusza
In recent years, cell-based therapies have emerged as a promising approach for mitigating radiation-induced injury. Acute radiation syndrome (ARS) results from exposure to high doses of radiation over a short time period. This study aimed to compare the efficacy of donor-recipient chimeric cell (DRCC) therapy in mitigating ARS induced by a total body irradiation (TBI) dose of 10 gray (Gy). Thirty irradiated Lewis rats were employed as ARS models to assess the efficacy of systemic-intraosseous transplantation of different cellular therapies in five experimental groups (n=6/group): saline control, isogeneic bone marrow transplantation (isoBMT), allogeneic BMT (alloBMT), DRCC, and alloBMT+DRCC...
May 16, 2024: Stem Cells and Development
https://read.qxmd.com/read/38753616/study-protocol-close-assessment-and-testing-for-chronic-graft-vs-host-disease-catch
#14
MULTICENTER STUDY
Joseph Pidala, Paul A Carpenter, Lynn Onstad, Steven Z Pavletic, Betty K Hamilton, George L Chen, Nosha Farhadfar, Marcie Hall, Stephanie J Lee
Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic cell transplantation. The "Close Assessment and Testing for Chronic GVHD (CATCH)" study is a multi-center Chronic GVHD Consortium prospective, longitudinal cohort study designed to enroll patients before hematopoietic cell transplantation and follow them closely to capture the development of chronic GVHD and to identify clinical and biologic biomarkers of chronic GVHD onset...
2024: PloS One
https://read.qxmd.com/read/38752476/treosulfan-is-a-safe-and-effective-alternative-to-busulfan-for-conditioning-in-adult-allogeneic-hsct-patients-data-from-a-single-center
#15
JOURNAL ARTICLE
Ant Uzay, Yasemin Gündoğdu, Barış Koşan, Tuğba Yetiş, S Sami Kartı
INTRODUCTION: Type of conditioning regimen impacts the outcome of patients who undergo allogeneic HSCT since graft versus host disease (GVHD), infections, regimen related toxicities (RRT) are important causes of post-transplant mortality. Despite the RRT profile of busulfan, it is frequently used worldwide. Treosulfan has advantages in terms of dose of administration, lower incidence of sinusoidal obstruction syndrome and lower neurotoxicity. We retrospectively investigated outcomes of patients who underwent allogeneic HSCT with treosulfan or busulfan based conditioning regimens in our institution...
May 2024: Cancer Medicine
https://read.qxmd.com/read/38751668/nutritional-and-body-composition-changes-in-paediatric-%C3%AE-thalassemia-patients-undergoing-hematopoietic-stem-cell-transplantation-a-retrospective-study-using-bioelectrical-impedance-analysis
#16
JOURNAL ARTICLE
Luyang Zhang, Li Wang, Jiewen Long, Yan Yin, Sandip Patil
OBJECTIVE: This retrospective study evaluated nutritional status and body composition changes in paediatric β-thalassemia (β-TM) patients before and after hematopoietic stem cell transplantation (HSCT), using bioelectrical impedance analysis (BIA), and explored their relationship with HSCT outcomes. METHODS: A cohort of 40 paediatric β-TM patients undergoing allogeneic HSCT was assessed for their nutritional status, anthropometric parameters, including body mass index (BMI), weight, and height, and body composition parameters pre-and post-HSCT, focusing on BIA measurements, including intracellular water (ICW), extracellular water (ECW), fat mass (FAT), fat-free mass (FFM), Skeletal Muscle Mass (SMM), soft Lean Mass (SLM), percent body fat (PBF), Body Cell Mass (BCM), Phase angle (PA) and muscle balance pre- and post-HSCT...
2024: Journal of Multidisciplinary Healthcare
https://read.qxmd.com/read/38750374/significance-of-absolute-neutrophil-count-before-allogeneic-hematopoietic-stem-cell-transplantation-in-adult-patients-with-aplastic-anemia
#17
JOURNAL ARTICLE
Yukinori Nakamura, Yoshitaka Zaimoku, Hiroki Yamaguchi, Hirohito Yamazaki, Minoru Kanaya, Naoyuki Uchida, Noriko Doki, Masatoshi Sakurai, Nobuhiro Hiramoto, Shinichi Kako, Makoto Onizuka, Koichi Onodera, Yumiko Maruyama, Hiroyuki Ohigashi, Tetsuya Nishida, Satoshi Yoshihara, Ken-Ichi Matsuoka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Yasushi Onishi
The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with aplastic anemia (AA) remains unclear. We retrospectively evaluated the relationship between ANC before transplantation and patient outcomes, involving 883 adult Japanese patients with AA who underwent allogeneic HSCT as their first transplantation between 2008 and 2020. Patients were divided into three groups based on ANC: 0/µL (n = 116); 1-199 (n = 210); and ≥ 200 (n = 557)...
May 16, 2024: Annals of Hematology
https://read.qxmd.com/read/38749910/successful-allogeneic-fecal-microbiota-transplantation-for-severe-diversion-colitis-a-case-report
#18
JOURNAL ARTICLE
Chuan-Li Cheng, Xiao-Jing Wang, Li-Xin Fan, Yong-Ling Lv, Kai Xiong, Zhi-Wei Jiang, Tian Gan, Guang Fu
Ileostomy diverts the flow of feces, which can result in malnutrition in the distal part of the intestine. The diversity of the gut microbiota consequently decreases, ultimately leading to intestinal dysbiosis and dysfunction. This condition can readily result in diversion colitis (DC). Potential treatment strategies include interventions targeting the gut microbiota. In this case study, we effectively treated a patient with severe DC by ileostomy and allogeneic fecal microbiota transplantation (FMT). A 69-year-old man presented with a perforated malignant tumor in the descending colon and an iliac abscess...
May 2024: Journal of International Medical Research
https://read.qxmd.com/read/38749067/allogeneic-haematopoietic-cell-transplantation-for-chronic-myeloid-leukaemia-in-switzerland-in-the-face-of-rapid-development-of-effective-drugs
#19
JOURNAL ARTICLE
Dominik Heim, Helen Baldomero, Michael Medinger, Stavroula Masouridi-Levrat, Urs Schanz, Gayathri Nair, Tayfun Güngör, Jörg Halter, Jakob R Passweg, Yves Chalandon
AIM: Until the year 2000, allogeneic haematopoietic cell transplantation (HCT) was the standard treatment for young and fit chronic myeloid leukaemia (CML) patients. CML was the main indication for allogeneic HCT. The introduction of tyrosine kinase inhibitors changed the treatment of CML patients dramatically. Allogeneic HCT was rapidly replaced by tyrosine kinase inhibitors as first-line treatment for CML, and the indication shifted to the treatment of non-responders, patients intolerant to tyrosine kinase inhibitors and patients whose CML is transforming to the accelerated phase and blast crisis...
May 3, 2024: Swiss Medical Weekly
https://read.qxmd.com/read/38748871/active-infection-at-the-time-of-cd34-selected-stem-cell-boost-is-associated-with-treatment-failure-and-poor-survival
#20
JOURNAL ARTICLE
Roman M Shapiro, Haesook T Kim, Remy Dulery, Deborah Liney, Heather M Garrity, Kevin M Panaro, Chloe Au, Casey Gervais, Jessica S Little, Vincent T Ho, Corey S Cutler, John Koreth, Mahasweta Gooptu, Joseph H Antin, Amar H Kelkar, Rizwan Romee, Catherine J Wu, Jerome Ritz, Robert J Soiffer, Sarah Nikiforow
BACKGROUND: The use of CD34+ selected stem cell boost (SCB) post allogeneic hematopoietic cell transplant (alloHCT) has been increasing. Predictors of treatment failure following SCB, both in the context of poor graft function (PGF) or other settings, are not well-characterized. We report among the largest single center retrospective experiences of the use of SCB and evaluate potential predictors of response and outcomes. METHODS: 58 patients who underwent HCT between 2015 and 2022 and who received SCB were identified...
May 15, 2024: Blood Advances
keyword
keyword
82751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.